Clinical outcomes at 12 months and risk of inflammatory bowel disease in patients with an intermediate raised fecal calprotectin: a ‘real-world’ view

OBJECTIVES: A recent systematic review confirmed the usefulness of fecal calprotectin (FC) in distinguishing organic (inflammatory bowel disease (IBD)) from non-organic gastrointestinal disease (irritable bowel syndrome (IBS)). FC levels <50 μg/g have a negative predictive value >92% to exclud...

Descripción completa

Detalles Bibliográficos
Autores principales: McFarlane, Michael, Chambers, Samantha, Malik, Ahmad, Lee, Bee, Sung, Edmond, Nwokolo, Chuka, Waugh, Norman, Arasaradnam, Ramesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Gastroenterology and Hepatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4908885/
https://www.ncbi.nlm.nih.gov/pubmed/27266773
http://dx.doi.org/10.1136/bmjopen-2016-011041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4908885/
https://www.ncbi.nlm.nih.gov/pubmed/27266773
http://dx.doi.org/10.1136/bmjopen-2016-011041

Ejemplares similares